Skip to Content
DiagnosticsDiagnostics
  • Review
  • Open Access

19 November 2026

17 Pages

From Bench to Bedside: Clinical Translation of Electrochemical Biosensors for Viral Diagnostics

and
1
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80324, Jeddah 21589, Saudi Arabia
2
Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 128442, Jeddah 21362, Saudi Arabia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.

Abstract

Electrochemical biosensors have emerged as promising platforms for rapid viral diagnostics, offering high analytical sensitivity, portability, short detection times, and potential compatibility with point-of-care testing. Advances in electrode nanostructuring, biorecognition strategies, signal amplification, and miniaturized instrumentation have enabled remarkably low limits of detection, reaching femtomolar and attomolar concentrations for synthetic viral targets under optimized experimental conditions. However, exceptional analytical performance under controlled conditions does not necessarily translate into clinical diagnostic utility. This review examines the progression of electrochemical biosensors from analytical proof-of-concept toward clinical application, emphasizing the evidence required for successful translation. Following a brief overview of viral targets, recognition strategies, and electrochemical detection approaches, particular attention is given to studies evaluating authentic clinical specimens, including those targeting SARS-CoV-2, dengue virus, human papillomavirus, and hepatitis C virus. Despite encouraging findings, clinical validation remains limited by small sample sizes, incomplete reporting of diagnostic sensitivity and specificity, and insufficient multicentre evaluation, while many platforms have been assessed only using artificial or spiked matrices. Additional challenges include matrix interference, biofouling, reproducibility, sample preparation, manufacturing consistency, stability, workflow integration, and regulatory requirements. Importantly, analytical limits of detection must be interpreted in relation to viral biology, specimen characteristics, clinically relevant thresholds, and intended clinical use. Future research should prioritize reproducible sample-to-answer performance over increasingly extreme analytical sensitivity. Accordingly, this review proposes a staged translational framework encompassing native-matrix analytical validation, adequately powered clinical studies, multicentre reproducibility, manufacturing and usability assessments, and regulatory evaluation. Ultimately, the clinical adoption of electrochemical biosensors will depend on robust evidence demonstrating reliable diagnostic performance in real-world healthcare settings.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.